SLC16A8

Across TCGA pan-cancer cohorts, SLC16A8 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SLC16A8’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SLC16A8 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC16A8 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

COAD, LSCC, and HNSC are the cancer types where SLC16A8 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC16A8 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	III,IV	+0.541	.002	9	view →
LSCC	All	All	+1.319	<.001	6	view →
HNSC	All	II,III,IV	+0.854	.032	4	view →
PDAC	All	All	−0.553	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SLC16A8–COAD

Open the COAD breakdown →